ArticleInternational journal of nanomedicine2020
Antiviral Activity of Chitosan Nanoparticles Encapsulating Curcumin Against Hepatitis C Virus Genotype 4a in Human Hepatoma Cell Lines.
Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 107 citations in OpenAlex.
- Characterization and bioactivity of Fusarium incarnatum Nano-chitosan.Journal, genetic engineering & biotechnology · 2026Article
- Magnetic graphene-based ferrite nanoparticles: synthesis, characterization, and anti-proliferative activity against some human cancer cells (RSC advances · 2026Article
- Nanomedicine in maternal viral infections: advancing prenatal therapies for fetal protection.Discover nano · 2026Review
- Visible-Light-Driven Photoactivity of Copper/PVA Composite Films against Murine Coronavirus.ACS omega · 2025Article
- Curcumin Nanoparticles-related Non-invasive Tumor Therapy, and Cardiotoxicity Relieve.Current medicinal chemistry · 2025Review
- Facile synthesis of FeScientific reports · 2024Article
- Review
- Nano-Enabled Antivirals for Overcoming Antibody Escaped Mutations Based SARS-CoV-2 Waves.International journal of molecular sciences · 2023Review
- Cerium Oxide Nanoparticles/Polyacrylonitrile Nanofibers as Impervious Barrier against Viral Infections.Pharmaceutics · 2023Article
- Chitosan-Based Nano-Smart Drug Delivery System in Breast Cancer Therapy.Pharmaceutics · 2023Review
- Early cancer detection using the fluorescent Ashwagandha chitosan nanoparticles combined with near-infrared light diffusion characterization: in vitro study.Lasers in medical science · 2023Article
- Application of antimicrobial, potential hazard and mitigation plans.Environmental research · 2022Review
- Article
- Chitosan and its derivatives as polymeric anti-viral therapeutics and potential anti-SARS-CoV-2 nanomedicine.Carbohydrate polymers · 2022Review
- Curcumin and Its Analogs as a Therapeutic Strategy in Infections Caused by RNA Genome Viruses.Food and environmental virology · 2022Review
- Antiviral activity of chitosan nanoparticles encapsulating silymarin (Sil-CNPs) against SARS-CoV-2 (RSC advances · 2022Article
- Antiviral Polymers: A Review.Polymers · 2022Review
- Antiviral and cytotoxic effects of a traditional drugJournal of King Saud University. Science · 2022Article
- Drug release study of the chitosan-based nanoparticles.Heliyon · 2022Review
- A review of the antiviral activity of Chitosan, including patented applications and its potential use against COVID-19.Journal of applied microbiology · 2022Review
Corrections and comments
- Correction · 2021-03-05Error in Image · Updated to Retraction ·
- Retraction · 2022-07-05Concerns/Issues about Third Party Involvement · Duplication of/in Image · Unreliable Data · Unreliable Results and/or Conclusions · Upgrade/Update of Prior Notice(s) ·
- Erratum issued
- Retracted
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCurrent direct-acting antiviral agents for treatment of hepatitis C virus genotype 4a (HCV-4a) have been reported to cause adverse effects, and therefore less toxic antivirals are needed. This study investigated the role of curcumin chitosan (CuCs) nanocomposite as a potential anti-HCV-4a agent in human hepatoma cells Huh7.
methodsDocking of curcumin and CuCs nanocomposite and binding energy calculations were carried out. Chitosan nanoparticles (CsNPs) and CuCs nanocomposite were prepared with an ionic gelation method and characterized with TEM, zeta size and potential, and HPLC to calculate encapsulation efficiency. Cytotoxicity studies were performed on Huh7 cells using MTT assay and confirmed with cellular and molecular assays. Anti-HCV-4a activity was determined using real-time PCR and Western blot.
resultsThe strength of binding interactions between protein ligand complexes gave scores with NS3 protease, NS5A polymerase, and NS5B polymerase of -124.91, -159.02, and -129.16, for curcumin respectively, and -68.51, -54.52, and -157.63 for CuCs nanocomposite, respectively. CuCs nanocomposite was prepared at sizes 29-39.5 nm and charges of 33 mV. HPLC detected 4% of curcumin encapsulated into CsNPs. IC50 was 8 µg/mL for curcumin and 25 µg/mL for the nanocomposite on Huh7 but was 25.8 µg/mL and 34 µg/mL on WISH cells. CsNPs had no cytotoxic effect on tested cell lines. Apoptotic genes' expression revealed the caspase-dependent pathway mechanism. CsNPs and CuCs nanocomposite demonstrated 100% inhibition of viral entry and replication, which was confirmed with HCV core protein expression.
conclusionCuCs nanocomposite inhibited HCV-4a entry and replication compared to curcumin alone, suggesting its potential role as an effective therapeutic agent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.